Suchergebnisse - "Subbiah, Vivek"

PubPharm (568)

101

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors : A Multicenter International Phase I/II Trial (ILLUMINATE-101)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Babiker, H. | Borazanci, E. | Subbiah, V. | +20

CommentIn: Clin Cancer Res. 2022 Dec 1;28(23):5007-5009. - PMID 36161479

102

Exportin(g) precision oncology beyond genomics with XPO1 inhibition

enthalten in: Med (New York, N.Y.) | 2022

von Gouda, M. | Subbiah, V.

CommentOn: Med (N Y). 2022 Nov 11;3(11):774-791.e7. - PMID 36195086

103

Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment

enthalten in: JAMA network open | 2022

von Ramagopalan, S. | Popat, S. | Gupta, A. | +9

104

Evolving Landscape of Antibody Drug Conjugates in Lymphoma

enthalten in: Cancer journal (Sudbury, Mass.) | 2022

von Prakash, R. | Subbiah, V. | Iyer, S.

105

Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy

enthalten in: Cancer journal (Sudbury, Mass.) | 2022

von Gouda, M. | Subbiah, V.

106

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

enthalten in: NPJ precision oncology | 2022

von Vo, H. | Fu, S. | Hong, D. | +20

107

Drugging KRAS : current perspectives and state-of-art review

enthalten in: Journal of hematology & oncology | 2022

von Parikh, K. | Banna, G. | Liu, S. | +4

108

Drugging KRAS: current perspectives and state-of-art review

enthalten in: Journal of hematology & oncology | 2022

von Parikh, K. | Banna, G. | Liu, S. | +4

109

Drugging KRAS: current perspectives and state-of-art review

enthalten in: Journal of hematology & oncology | 2022

von Parikh, K. | Banna, G. | Liu, S. | +4

110

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663